Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELEVATE: CMV DC Vaccine with Tetanus Pre-conditioning in GBM
NCT02366728Phase 2Completed
- Start
- Oct 2015
- Primary completion
- Oct 2020
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CMV pp65-LAMP mRNA-pulsed autologous dendritic cells in glioblastoma (GBM). Started Oct 2015; status: completed.
02
Drugs
CMV pp65-LAMP mRNA-pulsed autologous dendritic cells
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02366728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02366728.